References
- Global Burden of Disease Cancer Collaboration; Fitzmaurice C, Allen C, et al. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 cancer groups, 1990 to 2015: a systematic analysis for the global burden of disease study. JAMA Oncol. 2016. [Epub ahead of print].
- Loeb S, Bjurlin MA, Nicholson J, et al. Overdiagnosis and overtreatment of prostate cancer. Eur Urol. 2014;65(6):1046–1055.
- Kweldam CF, Wildhagen MF, Bangma CH, et al. Disease-specific death and metastasis do not occur in patients with Gleason score </=6 at radical prostatectomy. BJU Int. 2015;116(2):230–235.
- Albertsen PC, Hanley JA, Fine J. 20-year outcomes following conservative management of clinically localized prostate cancer. JAMA. 2005;293(17):2095–2101.
- Center MM, Jemal A, Lortet-Tieulent J, et al. International variation in prostate cancer incidence and mortality rates. Eur Urol. 2012;61(6):1079–1092.
- Pinsky PF, Prorok PC, Yu K, et al. Extended mortality results for prostate cancer screening in the PLCO trial with median follow-up of 15 years. Cancer. 2017;123(4):592–599.
- Schröder FH, Hugosson J, Roobol MJ, et al. Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up. Lancet. 2014;384(9959):2027–2035.
- Galper SL, Chen M-H, Catalona WJ, et al. Evidence to support a continued stage migration and decrease in prostate cancer specific mortality. J Urol. 2006;175(3 Pt 1):907–912.
- Roth JA, Gulati R, Gore JL, et al. Economic analysis of prostate-specific antigen screening and selective treatment strategies. JAMA Oncol. 2016;2(7):890–898.
- Fleshner K, Carlsson SV, Roobol MJ. The effect of the USPSTF PSA screening recommendation on prostate cancer incidence patterns in the USA. Nat Rev Urol. 2017;14(1):26–37.
- Tosoian JJ, Carter HB, Lepor A, et al. Active surveillance for prostate cancer: current evidence and contemporary state of practice. Nat Rev Urol. 2016;13(4):205–215.
- Bokhorst LP, Valdagni R, Rannikko A, et al. A decade of active surveillance in the PRIAS study: an update and evaluation of the criteria used to recommend a switch to active treatment. Eur Urol. 2016;70:954–960.
- Hamdy FC, Donovan JL, Lane JA, et al. 10-year outcomes after monitoring, surgery, or radiotherapy for localized prostate cancer. N Engl J Med. 2016;375(15):1415–1424.
- Klotz L, Vesprini D, Sethukavalan P, et al. Long-term follow-up of a large active surveillance cohort of patients with prostate cancer. J Clin Oncol. 2015;33(3):272–277.
- Bellardita L, Valdagni R, van den Bergh R, et al. How does active surveillance for prostate cancer affect quality of life? A systematic review. Eur Urol. 2015;67(4):637–645.
- Carlsson SV, de Carvalho TM, Roobol MJ, et al. Estimating the harms and benefits of prostate cancer screening as used in common practice versus recommended good practice: a microsimulation screening analysis. Cancer. 2016;122(21):3386–3393.
- Hayes JH, Barry MJ, McMahon PM. Observation versus initial treatment for prostate cancer. Ann Int Med. 2013;159(8):574.
- Venderbos LD, Roobol MJ, Bangma CH, et al. Rule-based versus probabilistic selection for active surveillance using three definitions of insignificant prostate cancer. World J Urol. 2016;34(2):253–260.
- Ankerst DP, Xia J, Thompson IM Jr, et al. Precision medicine in active surveillance for prostate cancer: development of the canary-early detection research network active surveillance biopsy risk calculator. Eur Urol. 2015;68(6):1083–1088.
- Ahmed HU, El-Shater Bosaily A, Brown LC, et al. Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study. Lancet. 2017;389(10071):815–822.
- Schoots IG, Petrides N, Giganti F, et al. Magnetic resonance imaging in active surveillance of prostate cancer: a systematic review. Eur Urol. 2015;67(4):627–636.